Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yajuan Qin
Observed names:
Ya-Juan Qin,
Yajuan Gu Qin,
Ya‐Juan Qin
Institution:
Xinjiang Medical University
Observed institutions:
Northwestern University,
Xinjiang Medical University,
Tumor Hospital of Xinjiang Medical University,
Adc Therapeutics (Switzerland),
State Key Laboratory of Pharmaceutical Biotechnology,
Chemistry of Life Processes Institute,
Nanjing University
show all 7
ORCID:
0000-0001-6757-0049
Observed ORCID:
0000-0001-6757-0049
OpenAlex ID:
A5101701854
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
2021
·
Paolo F Caimi
, Weiyun Ai
, et al.
·
The Lancet Oncology
·
473
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
2020
·
Mehdi Hamadani
, John Radford
, et al.
·
Blood
·
186
PDF
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
2023
·
Paolo F. Caimi
, Weiyun Z. Ai
, et al.
·
Haematologica
·
94
PDF
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
2020
·
Nitin Jain
, Wendy Stock
, et al.
·
Blood Advances
·
59
PDF
Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker
2016
·
Heng-Yen Wang
, Yajuan Qin
, et al.
·
Journal of Medicinal Chemistry
·
33
Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerization
2020
·
Jaspreet Banga
, Dinesh Srinivasan
, et al.
·
Science Advances
·
30
Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors
2013
·
Dong-Dong Li
, Ya-Juan Qin
, et al.
·
PLoS ONE
·
23
PDF
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2020
·
Paolo F Caimi
, Weiyun Z. Ai
, et al.
·
Blood
·
17
Comparison of double antigen sandwich and indirect enzyme‐linked immunosorbent assay for the diagnosis of hepatitis C virus antibodies
2020
·
Ya‐Juan Qin
, Ruo‐cheng Sha
, et al.
·
Journal of Clinical Laboratory Analysis
·
17
PDF
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
2022
·
Juan P. Alderuccio
, Weiyun Z. Ai
, et al.
·
Blood Advances
·
9
PDF
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial
2023
·
Mehdi Hamadani
, Alexander Spira
, et al.
·
Blood Advances
·
8
PDF
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019
·
Carmelo Carlo-Stella
, Pier Luigi Luigi Zinzani
, et al.
·
Blood
·
8
Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.
2021
·
Paolo Caimi
, Weiyun Z. Ai
, et al.
·
Journal of Clinical Oncology
·
5
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).
2023
·
Brian T. Hess
, Melhem M. Solh
, et al.
·
Journal of Clinical Oncology
·
4
PDF
P1132: Long-term Responses With Loncastuximab Tesirine: Updated Results From Lotis-2, the Pivotal Phase 2 Study in Patients With Relapsed/refractory Diffuse Large B-cell Lymphoma
2023
·
Paolo F Caimi
, Weiyun Z Ai
, et al.
·
HemaSphere
·
3
A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)
2022
·
Brian T. Hess
, Graham P. Collins
, et al.
·
Blood
·
3
Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial
2021
·
Juan Pablo Alderuccio
, Weiyun Z. Ai
, et al.
·
Blood
·
3
ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2021
·
Brad S. Kahl
, Mehdi Hamadani
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
3
LncRNA SNHG15 targets miR-200a-3p affects the proliferation, apoptosis, migration, and invasion of cervical cancer cells
2025
·
Songtao Han
, Yajuan Qin
, et al.
·
BMC Cancer
·
2
PDF
Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2023
·
David M. Kurtz
, Gregory Hogan
, et al.
·
Blood
PDF
POSTER: ABCL-134 Phase Ib Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7)
2023
·
Brian Hess
, Melhem Solh
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PDF
ABCL-134 Phase Ib Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7)
2023
·
Brian Hess
, Melhem Solh
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Abstract 5387: Discovery of plasma protein biomarkers associated with overall survival in R/R DLBCL patients treated with loncastuximab tesirine
2023
·
Francesco Vallania
, Victoria Cheung
, et al.
·
Cancer Research
Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)
2022
·
Francesco Vallania
, Victoria Cheung
, et al.
·
Blood
Oral Abstract: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2021
·
Brad S. Kahl
, Mehdi Hamadani
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
26
Citation count:
1,016
H-index:
9
I10-index:
9
Year
Topic
Type